Home Featured Page 222

Featured

Latest

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on Psychedelic Science, AI, and Idealist Monism

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Psychedelic Bulletin: Compass Pathways Secures 5th Patent; atai to Develop Salvinorin...

Cybin Announces Additional Adelia Milestone Achievements

Bexson Biomedical Launches New Project, Applying Subcutaneous Delivery Technology To Multiple...

Psilera Initiates Landmark Preclinical Studies with New Psychedelic Derivatives aimed at...

Mindset Pharma Announces Publication of Three PCT Patent Applications for Its...

atai Life Sciences Reports Second Quarter 2021 Financial Results and Business...

Beckley Psytech completes oversubscribed $80m (£58m) fundraise to develop portfolio of...

Why Does The Psychedelic Scene Ignore PCP? [Part 1]

PT257 – Robin Divine – Black People Trip

PTSF71 – Sexual Ethics in Psychedelics and Mistrust of Big Pharma

1...221222223...292 Page 222 of 292

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on...

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on Psychedelic Science, AI, and Idealist Monism

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Psychedelic Bulletin: Compass Pathways Secures 5th Patent; atai to Develop Salvinorin...

Cybin Announces Additional Adelia Milestone Achievements

Bexson Biomedical Launches New Project, Applying Subcutaneous Delivery Technology To Multiple...

Psilera Initiates Landmark Preclinical Studies with New Psychedelic Derivatives aimed at...

Mindset Pharma Announces Publication of Three PCT Patent Applications for Its...

atai Life Sciences Reports Second Quarter 2021 Financial Results and Business...

Beckley Psytech completes oversubscribed $80m (£58m) fundraise to develop portfolio of...

Why Does The Psychedelic Scene Ignore PCP? [Part 1]

PT257 – Robin Divine – Black People Trip

PTSF71 – Sexual Ethics in Psychedelics and Mistrust of Big Pharma

EDITOR PICKS

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on...

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY